Evidence map›Paper›PMID 18645606›Full record

ArticleInternational journal of medical sciences2008

Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis.

Walter Fries, Carmelo Muja, Carmela Crisafulli, Giuseppe Costantino, Giuseppe Longo, Salvatore Cuzzocrea, Emanuela Mazzon

Open access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 57 citations in OpenAlex.

  1. Acoustic percolation switches enable targeted drug delivery controlled by diagnostic ultrasound.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Etanercept protects rat cardiomyocytes against hypertrophy by regulating inflammatory cytokines secretion and cell apoptosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Etanercept biosimilars.Rheumatology international · 2015
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Walter FriesDipartimento di Medicina Interna e Terapia Medica, Sezione di Farmacologia, Università di Messina, Messina, Italy. fwalter@unime.it
Carmelo Muja
Carmela Crisafulli
Giuseppe Costantino
Giuseppe Longo
Salvatore Cuzzocrea
Emanuela Mazzon
University of Messina · ITCentro Neurolesi Bonino Pulejo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of epithelial barrier integrity is considered an early step in the pathogenesis of Crohn's disease (CD), and the rate of enterocyte apoptosis is one of the determinants of the intestinal barrier function. Tumor necrosis factor-alpha (TNF-alpha), one of the major proinflammatory mediators in CD, is one of the extrinsic signals which initiate apoptosis of enterocytes. The aim of this study was to investigate the early effects of experimental colitis on enterocyte apoptosis, and the effects of two anti-TNF treatments, infliximab (IFX) and etanercept (ETC). In addition, the importance of receptor I for TNF was tested in TNFR-1(-/- )mice. Circulating TNF-alpha levels were effectively reduced by IFX and ETC (p<0.01, both) at 3 and 6 h. Apoptosis of the ileal enterocytes, assessed by TUNEL staining, staining for Fas-ligand, and bax, increased at 3 and 6h. These alterations were prevented by both anti-TNF strategies, and in TNFR-1(-/-) animals. The anti-apoptotic protein Bcl-2 was expressed in the ileal epithelium under control conditions, but was suppressed in DNB-colitis. Expression of Bcl-2 was maintained in both anti-TNF treatments and TNFR-1(-/-) mice.DNB colitis induced a very early, rapid increase of enterocyte apoptosis. Both anti-TNF strategies, IFX and ETC, were equally effective in suppressing enterocyte apoptosis, most likely by inactivation of circulating TNF-alpha.

Indexed as

AnimalsAntibodies, MonoclonalAnti-Inflammatory AgentsApoptosisBenzenesulfonatesBlotting, WesternColitisDisease Models, AnimalEnterocytesEtanerceptFas Ligand ProteinImmunoglobulin GImmunohistochemistryInfliximabIn Situ Nick-End LabelingMaleAntibodies, MonoclonalAnti-Inflammatory AgentsBenzenesulfonatesdinitrobenzenesulfonic acidEtanerceptFas Ligand ProteinImmunoglobulin GInfliximabProto-Oncogene Proteins c-bcl-2Receptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type ITumor Necrosis Factor-alphaApoptosisEnterocyteExperimental ColitisTNF-α

Identifiers

PMID18645606
PMCPMC2452978
OpenAlexW2064385743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.